CD19 and diffuse large B-cell lymphoma: The 65-year-old patient presented with progressive shock due to CRS on the fourth day after receiving CD19-specific CAR-T cells (YESCARTA®, 0.4–2.0 × 108 cells) for refractory diffuse large B-cell lymphoma (DLBCL).